Currently out of the existing stock ratings of Jonathan Wolleben, 234 are a BUY (99.57%), 1 are a HOLD (0.43%).

Jonathan Wolleben

Work Performance Price Targets & Ratings Chart

Analyst Jonathan Wolleben, carries an average stock price target met ratio of 30.05% that have a potential upside of 41% achieved within 187 days. Previously, Jonathan Wolleben worked at JMP.

Jonathan Wolleben’s has documented 458 price targets and ratings displayed on 23 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on SGMT, Sagimet Biosciences Series A Common Stock at 14-Nov-2025.

Wall Street Analyst Jonathan Wolleben

Analyst best performing recommendations are on RYTM (RHYTHM PHARMACEUTICALS).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 6/26/2025. The price target of $84 was fulfilled within 13 days with a profit of $22.55 (36.7%) receiving and performance score of 28.23.

Average potential price target upside

of $138.65 (76.53%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $36.69 (119.64%) on MIRM (MIRUM PHARMACEUTICALS).
of $21.86 (92.42%) on CRNX (CRINETICS PHARMACEUTICALS).

ALT Altimmune CLSD Clearside Biomedical CRNX Crinetics Pharmaceuticals DBVT DBV Technologies LRMR Larimar Therapeutics OCUL Ocular Therapeutix PRQR ProQR Therapeutics BV BCRX BioCryst Pharmaceuticals RLYB Rallybio Corp PHVS Pharvaris BV MDGL Madrigal Pharmaceuticals AURA Aura Biosciences PTGX Protagonist Therapeutics ALLK Allakos MIRM Mirum Pharmaceuticals SPRB Spruce Biosciences RYTM Rhythm Pharmaceuticals SVRA Savara GPCR Structure Therapeutics American Depositary Shares SGMT Sagimet Biosciences Series A Common Stock ATXS Astria Therapeutics KALV Kalvista Pharmaceuticals SKYE Skye Bioscience, Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jonathan Wolleben (JMP)